A phase I open-label multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers
Brief description of study
This study is a FIH, open-label, phase I, multi-center study that consists of two treatment arms in dose escalation: single-agent KFA115 (Arm A escalation) and KFA115 in combination with pembrolizumab preceded by a KFA115 run-in for 1 cycle (Arm B escalation). In expansion, the study consists of three treatment arms: single-agent KFA115 (Arm A expansion), KFA115 in combination with pembrolizumab after single-agent KFA115 run-in (Arm B expansion), and KFA115 to be initiated with pembrolizumab concurrently (Arm C expansion).
Clinical Study Identifier: s23-01023
ClinicalTrials.gov Identifier: NCT05544929
Principal Investigator:
Kristen Spencer.
Other Investigators:
Nila Theresa De La Rosa,
Joshua K Sabari,
Samantha VanMaanen,
Eneil De La Pena,
Salman Rafi Punekar,
Elaine Shum,
Jessica Wang,
Ann M Riccobene,
Janice Mehnert,
Scot Niglio,
Keriann M Scavone,
Zujun Li,
Elise M Zahriah,
Kathleen M Madden,
Nancy Chan,
Megan DiBenedetto,
David R. Wise,
Nina Beri,
Ruth A White,
Douglas K Marks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.